Research Paper

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease

Joseph Jacob a,g,⁎,1, Jin Woo Song b,y,⁎,1, Hee-Young Yoon b, Gary Cross c, Joseph Barnett c, Wen Ling Woo c, Fern Adams c, Maria Kokosi d, Anand Devaraje, Elisabetta Renzoni d, Toby M. Maher d,f, Dong Soon Kim b,⁎, Athol U. Wells d

a Division of Radiology, Mayo Clinic Rochester, Rochester, MN, USA
b Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
b Department of Radiology, Royal Free Hospital NHS Foundation Trust, London, UK
c Interstitial Lung Disease Unit, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK
d Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London
e Department of Radiology, Royal College of Surgeons in Ireland, Dublin, Ireland
f Department of Radiology, University College London, London, UK

ARTICLE INFO

Article history:
Received 8 December 2017
Received in revised form 26 January 2018
Accepted 26 January 2018
Available online xxx

Keywords:
Rheumatoid arthritis
Interstitial lung disease
Emphysema
Computed tomography

ABSTRACT

Aims: Autoimmune conditions such as rheumatoid arthritis-related interstitial lung disease (RA-ILD) have been linked to the existence of emphysema in never-smokers. We aimed to quantify emphysema prevalence in RA-ILD never-smokers and investigate whether combined pulmonary fibrosis and emphysema (CPFE) results in a worsened prognosis independent of baseline disease extent.

Methods: RA-ILD patients presenting to the Royal Brompton Hospital (n = 90) and Asan Medical Center (n = 155) had CT’s evaluated for a definite usual interstitial pneumonia (UIP) pattern, and visual extents of emphysema and ILD. Results: Emphysema, identified in 31/116 (27%) RA-ILD never-smokers, was associated with obstructive functional indices and conformed to a CPFE phenotype: disproportionate reduction in gas transfer (DLco), relative preservation of lung volumes. Using multivariate logistic regression, adjusted for patient age, gender and ILD extent, emphysema presence independently associated with a CT-UIP pattern in never-smokers (0.009) and smokers (0.02). On multivariate Cox analysis, following adjustment for patient age, gender, DLco, and a CT-UIP pattern, emphysema presence (representing the CPFE phenotype) independently associated with mortality in never-smokers (p = 0.04) and smokers (p < 0.05).

Conclusion: 27% of RA-ILD never-smokers demonstrate emphysema on CT. Emphysema presence in never-smokers independently associates with a definite CT-UIP pattern and a worsened outcome following adjustment for baseline disease severity.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

In rheumatoid arthritis-related interstitial lung disease (RA-ILD), the prevalence of smoking ranges between 38–72% (Kim et al., 2010; Tsuchiya et al., 2011; Kelly et al., 2014; Antoniou et al., 2013; Saag et al., 1996; Yunt et al., 2017). Smoking has been implicated in the development of emphysema in patients with chronic obstructive pulmonary disease (COPD) than the general population, with results maintained following modelling for potential confounding effects of smoking (McGuire et al., 2017).

Emphysema has previously been identified in never-smokers in an underpowered cohort of patients with rheumatoid lung (8) and in 7.5% of a large cohort of never-smokers with scleroderma-associated pulmonary fibrosis (13). Autoimmune pathways have been linked to the development of emphysema in patients with COPD (Zhang et al., 2014; Feghali-Bostwick et al., 2008; Packard et al., 2013) and may underlie the occurrence of emphysema in never-smokers with fibrosing lung disease (Antoniou et al., 2013; Antoniou et al., 2015).

Please cite this article as: Jacob, J., et al., Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.038

https://doi.org/10.1016/j.ebiom.2018.01.038

2352-3964/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
It has been suggested that in patients with connective tissue disease related ILD, emphysema adversely affects prognosis by increasing the likelihood of developing pulmonary hypertension (PHT) (Cottin et al., 2011). However, in a contemporary study of IPF patients, combined pulmonary fibrosis and emphysema (CPFE) was not associated with a worsened outcome beyond that explained by the baseline CT disease extents of emphysema and ILD (Jacob et al., 2017).

Prompted by a recent position paper on RA-ILD encouraging future analyses of cohorts from multiple centres (Doyle et al., 2014), and a meta-analysis emphasizing the small sample sizes associated with the majority of prior RA-ILD studies (Assayag et al., 2014), our study examined two large RA-ILD cohorts to answer three questions. Firstly, we quantified emphysema prevalence in never-smokers with RA-ILD. Secondly, in never-smokers, we examined whether the presence of emphysema links to a definite usual interstitial pneumonia (UIP) pattern (Raghu et al., 2011) on CT, identified as being a poor prognostic marker in RA-ILD (Kim et al., 2010; Tsuchiya et al., 2011; Kelly et al., 2014; Yunt et al., 2017; Assayag et al., 2014). Lastly, we investigated whether CPFE has a worsened prognosis in RA-ILD, over and above the extent of emphysema and ILD.

2. Methods

2.1. Clinical Data

A retrospective analysis of an ILD database identified all new consecutive patients presenting between January 2007 to July 2014 at the Royal Brompton Hospital, London, and from May 1995 to May 2015 at the Asan Medical Center, Seoul. Patients with a diagnosis of RA-ILD as confirmed on multidisciplinary team review were identified. The diagnosis of rheumatoid arthritis was made according to the American College of Rheumatology/European League Against Rheumatism criteria (Aletaha et al., 2010). Patients were defined as “ever smokers” following evaluation of clinical notes if they had smoked at least one cigarette per day for at least one year.

Approval for this study of clinically indicated CT and pulmonary function data was obtained from the Institutional Ethics Committee of the Royal Brompton Hospital and the Institutional Review Board of the Asan Medical Center, Seoul, Korea and informed patient consent was not required.

2.2. CT Evaluation

CT and pulmonary function protocols are described in the Supplementary Appendix. Each CT scan was evaluated independently by two radiologists (GC, JB) with 3 and 4 years imaging experience respectively, blinded to all clinical information. Interstitial CT parameters evaluated visually on a lobar basis included ground glass densities, reticulation and honeycombing (Jacob et al., 2017).

Emphysema was classified as being centrilobular and/or paraseptal and as thin-walled cystic lesions within areas of co-existent fibrosis (Inomata et al., 2014). Emphysema was further subcategorized into one of two types: geographically distinct from areas of fibrotic lung (non-admixed emphysema) and as emphysema lying within areas of fibrosis (admixed emphysema) as previously described (Jacob et al., 2017). The total extent of emphysema was quantified on a lobar basis and the proportion of admixed emphysematous lung was recorded. The percentage of admixed emphysema was derived as follows:

\[
\text{Percent admixed emphysema} = \left( \frac{\text{total emphysema} \times \text{proportion admixed}}{100} \right)
\]

The percentage of non-admixed emphysema represented the remainder of the scored emphysema. All CT variables were expressed as a percentage of the total lung volume. Total ILD extent represented the sum of ground glass opacities, reticulation and honeycombing. A definite radiological UIP pattern was defined using the ATS/ERS/JRS/ALAT consensus statement for IPF (Raghu et al., 2011) and was scored for each CT by a separate scorer (JJ), with 10 years imaging experience blinded to all clinical information.

2.3. Consensus Formulation for Visual Scores

Following visual CT scoring, the identification of systematic biases in visual scores was achieved by plotting the spread of differences in parenchymal pattern scores between observers. The most disparate 5% (two standard deviations) of values were arbitrated by a third scorer (JJ) as was any disagreement between scorers for the presence of either emphysema or honeycombing. Identification of emphysema in never-smokers was verified by the same third scorer (JJ).

2.4. Pulmonary Function Tests

Pulmonary function indices examined in the current study included forced expiratory volume in one second (FEV1), the diffusing capacity for carbon monoxide (DLco) and the carbon monoxide transfer coefficient (Kco).

3. Statistical Analysis

Data are given as means with standard deviations, or numbers of patients with percentages where appropriate. Interobserver variation for visual scores was assessed using the single determination standard deviation for continuous variables and as the Kappa statistic for categorical variables. Mean differences between groups were evaluated using a Chi-squared test for categorical variables or a two-sample t test for parametric continuous variables, and the Mann-Whitney U test for medians. Statistical significance was evaluated at a value of p < 0.05. Univariate and multivariate linear regression analyses were used to identify relationships between CT and functional indices. Univariate Cox proportional hazards analyses identified variables associated with outcome. Survival estimation was performed via the Kaplan Meier method. Two-sample survival comparisons were performed using the Log rank test.

Four main domains were evaluated in the study: i) prevalence of emphysema in never-smokers, ii) morality impact of CPFE in never-smokers, iii) association of emphysema with honeycombing (and separately evaluated as IPF-like and non-IPF-like) in never-smokers, iv) an associated CPFE functional profile in never-smokers with emphysema. Analyses performed in never-smokers were compared to parallel analyses in smokers acting as a control group. In all control-group models (smokers), adjustment was made for patient pack-year history.

A multivariate Cox proportional hazard model investigated whether a CPFE phenotype has an independent effect on outcome in never-smokers after adjusting for baseline disease extent (using DLco), patient age, gender, and baseline disease severity (using CT honeycomb presence). Baseline DLco was used to adjust for baseline disease extent as it captures disease secondary to interstitial fibrosis, emphysema and any associated pulmonary hypertension (Jacob et al., 2017). Baseline disease severity was measured using a CT definite UIP pattern as this has been well recognized as a robust measure of severity in RA-ILD patients.

A multivariate logistic regression model examined variables that were associated with the presence of a) honeycombing on CT in never-smokers and b) an ATS/ERS/JRS/ALAT consensus diagnosis of a definite UIP pattern on CT (Raghu et al., 2011). Both associations of CT honeycombing presence and a definite UIP pattern on CT were separately evaluated in the study to allow consideration of a UIP pattern (evidenced by honeycombing on CT) in RA-ILD, which would not strictly conform to the agreed definition of a UIP pattern in IPF, given differences in disease distribution in RA-ILD (less basal predominant disease, and more peribronchovascular fibrosis) compared to an IPF-like UIP pattern (Raghu et al., 2011). Variables inserted into the regression
model included patient age, gender, baseline ILD extent and emphysema presence. Model fit was evaluated using the C-statistic.

Lastly, using multivariate linear regression analyses, we examined whether never-smokers with emphysema displayed a CPFE lung functional profile, characterized by disproportionate DLco reduction and artificially preserved lung volumes. In each model, adjustment was made for patient age, gender, and baseline ILD extent. All positive logistic regression and proportional hazards models were re-run, adjusting for the study center. Assumptions of linearity and proportional hazards were tested by visual inspection of Martingale residuals and scaled Schoenfeld residuals and were satisfied. Statistical analyses were performed with SPSS (IBM SPSS Statistics for Macintosh, Version 20.0. (IBM Corp., Armonk, NY, USA).

4. Results

4.1. Demographic Data

90 patients presenting to the Royal Brompton Hospital and 155 patients presenting to the Asan Medical Center diagnosed with RA-ILD had vital status completed with no patients lost to follow up. Baseline differences between the populations at the two institutions are demonstrated in Supplementary Table 1. A significant difference in smoking rates between patients at the two institutions (p = 0.0003) [Table 1] was primarily explained by differences in smoking rates between women: female Asan ex-smokers = 7/88 (8%); female Brompton ex-smokers = 25/47 (53%)[p < 0.0001]. Smoking rates were similar amongst men in both institutions: male Asan ex-smokers = 61/67 (91%); male Brompton ex-smokers = 36/43 (84%) [p = 0.25]. Differences in baseline variables, across both cohorts, for RA-ILD patients with and without emphysema and between smokers and never-smokers are shown in Tables 1 and 2 respectively. Variation in visual CT scores for continuous variables, as measured by the single determination standard deviation, are shown in Supplementary Table 2. Kappa values for the two scorers for the presence of emphysema were 0.51. Survival curves for patients with and without honeycombing and with and without a definite UIP pattern on CT are shown in Fig. 1a and b respectively.

Across the entire study population, the presence of visually scored emphysema was associated with obstructive FEV1/FVC values on spirometry (β = −7.26, 95%CI −11.48, −3.04, p = 0.001) following adjustment for patient age, gender and baseline ILD extent. When quantified as percentages of the lung, emphysema lying distant to fibrotic lung (β = −0.75, 95%CI −0.96, −0.54, p < 0.0001) and emphysema admixed within fibrotic lung (β = −0.54, 95%CI −0.96, −0.12, p = 0.01) were also associated with obstructive values when inserted separately into the same models adjusted for patient age, gender, and baseline ILD extent.

Across the entire study population, the presence of visually scored honeycombing was associated with restrictive FEV1/FVC values on spirometry (Supplementary Table 3) following adjustment for patient age, gender and visual extents of reticular opacities and total emphysema. Whilst reticular opacities also demonstrated restrictive FEV1/FVC values, emphysema extent demonstrated restrictive FEV1/FVC values

Table 1

| Variable | Emphysema absent | Emphysema present | Group comparison |
|----------|------------------|-------------------|------------------|
| Units: percentages unless stated |  |  |  |
| Median age (years) | 62 | 63 | =0.86* |
| Male/female (ratio) | 25/91 | 85/44 | <0.0001* |
| Survival (alive/dead) | 80/36 | 55/74 | <0.0001* |
| Never/ever-smokers (ratio) | 85/31 | 31/98 | =0.01 |
| FEV1% predicted | 79.6 ± 21.1 (115) | 76.2 ± 20.7 (121) | =0.21 |
| FVC% predicted | 73.4 ± 18.0 (115) | 76.6 ± 21.7 (121) | =0.22 |
| DLco% predicted | 58.5 ± 19.8 (108) | 49.5 ± 20.5 (122) | =0.001 |
| Kco% predicted | 82.5 ± 17.8 (71) | 65.5 ± 17.7 (93) | <0.0001 |
| Visual ILD extent | 26.0 ± 16.9 | 28.9 ± 18.5 | =0.20 |
| Visual honeycombing extent | 2.4 ± 4.2 | 4.8 ± 8.4 | =0.006 |

Please cite this article as: Jacob, J. et al., Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.038
Emphysema was present on CT in 31/116 (27%, 95% confidence interval = 0.19–0.36) of never-smoking RA-ILD patients compared to 98/129 (76%) control smokers with RA-ILD (p < 0.0001). In never-smokers, emphysema was present in lung regions distant from pulmonary fibrosis (non-admixed) in 30/31 cases. Emphysema was also admixed within areas of pulmonary fibrosis in 25/31 cases. In one never-smoker, emphysema was admixed with fibrosis but was not present in non-fibrotic areas.

When all patients with emphysema were examined, never-smokers were found to have less extensive emphysema than smokers (p = 0.96). In patients with non-admixed emphysema, coexisting centrilobular and paraseptal emphysema was more common in smokers 71/97 (73%) than never-smokers 11/30 (37%) (p = 0.0003). In patients with either centrilobular or paraseptal emphysema, paraseptal emphysema 13/30 (43%) was more common than centrilobular emphysema 6/30 (20%) in never-smokers, and smokers (paraseptal emphysema: 23/97 [24%]; centrilobular emphysema: 3/97 [3%]). Thin walled cystic lesions (Inomata et al., 2014) were more common in smokers 14/97 (14%) than never-smokers 1/30 (3%) (p = 1.00) with non-admixed emphysema. In cases where thin walled cystic lesions were seen, centrilobular and paraseptal emphysema was always present. Admixed emphysema was predominantly identified in the lung bases and of similar extent in smokers and never-smokers (p = 0.08). The results were maintained following adjustment for total emphysema andILD extents.

Fig. 1. Kaplan Meier survival curves in subgroups of patients with rheumatoid arthritis related interstitial lung disease. a. Kaplan Meier survival curves were significantly different between RA-ILD patients with honeycombing on CT (green, n = 142, restricted mean survival = 91.0 ± 11.3) and RA-ILD patients without any honeycombing on CT (blue, n = 103, restricted mean survival = 136.1 ± 100). Log rank test p < 0.0001. b. Kaplan Meier survival curves were significantly different between RA-ILD patients with a definite UIP pattern on CT (green, n = 74, restricted mean survival = 141.9 ± 11.7 months). Log rank test p = 0.0002. c. Kaplan Meier survival curves were significantly different between RA-ILD patients without any emphysema on CT (blue, n = 116, restricted mean survival = 161.7 ± 13.6), and RA-ILD patients with emphysema scored visually on CT (green, n = 129, restricted mean survival = 129.9 ± 9.3) versus smokers (green; n = 129, restricted mean survival = 87.0 ± 11.5). Log rank test p = 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
4.3. Outcome Effects of Emphysema in RA-ILD Never-Smokers

Univariate Cox regression analysis demonstrated that increasing emphysema extent, as well as both emphysema subtypes (non-admixed and admixed) were strongly associated with mortality in never-smokers (Table 3). Functional indices did not strongly associate with outcome in never-smokers (Table 3) when compared to smokers (Supplementary Table 4). Outcome differences between patients with and without emphysema and between never-smokers and smokers are shown in Fig. 1c and d respectively.

On multivariate Cox regression analysis, after adjusting for patient age, gender, baseline disease extent using DLco, and a disease-associated with mortality (Table 4). All models were maintained after adjustment for CT, in never-smokers (and separately in smokers), the presence of emphysema and between never-smokers and smokers are shown in Fig. 1c and d respectively.

On multivariate Cox regression analysis, after adjusting for patient age, gender, baseline disease extent using DLco, and a disease-associated with mortality (Table 4). All models were maintained after adjustment for study center.

4.4. Associations of Honeycombing Presence on CT

In never-smokers, patient age, gender, ILD extent and emphysema presence were inserted into a multivariate logistic regression model (Table 5). The presence of emphysema (p = 0.005) was independently associated with the presence of honeycombing on CT (Model C-statistic = 0.71). The finding, though weaker in strength, was maintained in smokers (p = 0.02), after adjusting for smoking pack year history (Model C-statistic = 0.78). Emphysema presence also linked to a definite UIP pattern on CT (Table 5) in never-smokers (model C-statistic = 0.75) and smokers (model C-statistic = 0.77) when using the same logistic regression models.

The extent of ILD, whilst strongly associated with honeycombing presence in smokers (p = 0.001), did not associate with honeycombing presence in never-smokers and demonstrated no linkage to a definite UIP pattern in never-smokers and smokers (Table 5). All models were maintained after adjustment for study center.

4.5. Functional Effects of Emphysema in RA-ILD Never-Smokers

In never-smokers, a classic CPFE functional profile of a disproportionate reduction in DLco and artificially preserved lung volumes was not identified and was thought to be a consequence of the limited extents of emphysema in never-smokers (of the 81 study patients with over 5% emphysema, only 10/81 [12%] were never-smokers). When the functional effects of emphysema presence were examined across the whole study population, a CPFE functional profile was identified with results maintained at a 5% emphysema threshold (Supplementary Table 5). Across the entire study population, emphysema lying distant to fibrotic lung (non-admixed) demonstrated an independent negative association with DLco and Kco. In a similar adjusted model, an independent negative association was identified between admixed emphysema and Kco, but not DLco (Supplementary Table 6).

5. Discussion

Our study has identified several findings in patients with RA-ILD. Firstly, across two independent cohorts of patients, emphysema was identified in 27% of never-smokers. Secondly, in never-smokers, the presence of emphysema was independently associated with the presence of honeycombing on CT and a CT UIP pattern. Lastly, we demonstrated that the presence of emphysema, representing the CPFE phenotype, is independently associated with a worsened outcome in never-smokers and smokers with RA-ILD following adjustment for baseline disease severity.

Our study represents a detailed multicenter evaluation of emphysema and smoking burden in patients with RA-ILD. The primary study aim emerged from limited data in previous analyses of ILD cohorts, whereby emphysema had been identified in life-long never-smokers with IPF (Jacob et al., 2017), RA-ILD (Antoniou et al., 2013), and scleroderma (Antoniou et al., 2015). Since the cardinal question posed by our study revolved around the prevalence of emphysema, to avoid biases in emphysema characterization, all scorers were blinded to all clinical details. Reassuringly, the interobserver agreement for the presence of emphysema in our analyses was similar to previous CT descriptions of emphysema in patients with RA-ILD (Antoniou et al., 2013), scleroderma (Antoniou et al., 2015), and IPF (Jacob et al., 2017).

Four separate observations suggested that the scorers had avoided the misclassification of non-emphysematous lung as emphysema. Firstly, emphysema was scored more extensively in ever-smokers than never-smokers and proportions of emphysema separate to and occurring within fibrotic lung were similar in both patient groups. Secondly, in all but one case, when admixed emphysema was identified, emphysema was identified lying separate to fibrotic lung and was predominantly distributed within the upper lobes of the lung. Thirdly, parenchyma classified as both non-admixed and admixed emphysema was associated with obstructive functional indices. Furthermore, across the whole study population, the CPFE functional profile in RA-ILD mirrored the disproportionate reduction in gas transfer occurring with a relative preservation of lung volumes that has come to define the functional CPFE phenotype in IPF (Jacob et al., 2017; Ryerson et al., 2013; Cottin et al., 2005; Mejia et al., 2009; Bodlet et al., 2013; Mura et al., 2006). Lastly, honeycombing, which represents the CT pattern most likely to be confused with emphysema, was associated with restrictive functional indices when analyzed alongside emphysema extent which maintained its association with obstructive functional indices.

The presence of emphysema in 27% (95% confidence interval = 0.19–0.36) of never-smoker RA-ILD patients, whilst reinforcing observations in IPF (15% emphysema prevalence in never-smokers; measured using contiguous 1.0 mm CT images) (Jacob et al., 2017) and scleroderma (7% emphysema prevalence in never-smokers; measured using 1.5–3.0 mm thickness axial CT images) (Antoniou et al., 2015) was greater than that previously reported in patients with fibrosing lung diseases.

A study by Antoniou et al. (Antoniou et al., 2013) identified emphysema in 2/35 (6%) (Antoniou et al., 2013) never-smokers with RA-ILD, and in 22/46 (48%) of smokers with RA-ILD. The comparatively low prevalence of emphysema in never-smokers in the RA-ILD and scleroderma studies of Antoniou et al. (Antoniou et al., 2013; Antoniou et al., 2015) are likely to reflect fundamental differences in HRCT acquisition technique. The smaller RA-ILD study population of Antoniou et al.

| Variable | Units are percentage unless specified | Patient number | Hazard ratio | 95.0% confidence interval | P value |
|----------|--------------------------------------|----------------|-------------|--------------------------|--------|
|          |                                      |                |             |                          |        |
| Age (years) |                                      | 116            | 1.05        | 1.02 1.08                | 0.001  |
| Gender (M = 1, F = 0) |                                 | 116            | 1.49        | 0.57 3.84                | 0.41   |
| Visual CT scores |                                  |                |             |                          |        |
| ILD extent |                                      | 116            | 1.03        | 1.02 1.05                | <0.0001|
| Honeycombing extent |                                | 116            | 1.08        | 1.05 1.12                | <0.0001|
| Honeycombing presence |                               | 116            | 2.90        | 1.36 6.21                | 0.006  |
| Non-admixed emphysema |                           | 116            | 1.08        | 1.02 1.15                | 0.009  |
| Admixed emphysema |                                      | 116            | 1.11        | 1.04 1.18                | 0.002  |
| Total emphysema |                                      | 116            | 1.05        | 1.02 1.08                | 0.003  |
| Emphysema presence |                                   | 116            | 1.51        | 0.78 2.95                | 0.23   |
| Emphysema > 5% |                                     | 116            | 2.34        | 0.88 6.17                | 0.09   |
| Emphysema > 10% |                                    | 116            | 6.84        | 2.00 23.42                | 0.002  |
| Pulmonary Function Tests |                                  |                |             |                          |        |
| FVC |                                      | 115            | 0.97        | 0.95 0.99                | 0.009  |
| DLco |                                      | 111            | 0.98        | 0.96 1.00                | 0.02   |
| Kco |                                      | 110            | 0.97        | 0.95 1.00                | 0.03   |

Please cite this article as: Jacob, J., et al., Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.038
Table 4
Multivariate Cox proportional hazards regression models associated with mortality in never-smokers (Model 1) and smokers (Model 2) with RA-ILD, following correction for patient age, gender, a CT definite usual interstitial pneumonia (UIP) pattern and baseline disease extent using DLCO (diffusing capacity for carbon monoxide). Unadjusted hazard ratios are shown in brackets.

| Variable                                      | Hazard ratio ((unadj), adj) | 95.0% confidence interval | P value |
|-----------------------------------------------|-----------------------------|---------------------------|---------|
| Model 1                                        |                             |                           |         |
| Age                                           | (1.05) 1.06                 | 1.02                      | 1.09    | 0.003 |
| Gender                                        | (1.49) 0.86                 | 0.29                      | 2.55    | =0.78 |
| DLco                                          | (0.98) 0.98                 | 0.96                      | 1.00    | =0.02 |
| Emphysema presence                            | (1.51) 2.30                 | 1.02                      | 5.16    | =0.04 |
| CT definite UIP pattern                       | (1.71) 1.54                 | 0.72                      | 3.32    | =0.27 |
| Model 2                                        |                             |                           |         |
| Age                                           | (1.04) 1.04                 | 1.01                      | 1.07    | 0.006 |
| Gender                                        | (1.35) 0.85                 | 0.44                      | 1.63    | 0.64  |
| DLco                                          | (0.97) 0.97                 | 0.95                      | 0.98    | <0.0001 |
| Emphysema presence                            | (2.59) 2.16                 | 1.01                      | 4.62    | =0.047 |
| CT definite UIP pattern                       | (2.26) 2.13                 | 1.24                      | 3.65    | =0.006 |

The presence of emphysema was linked to an adverse outcome in both never-smokers and smokers with RA-ILD and runs counter to a recent report in IPF patients where, following analogous correction for baseline disease extent, CPFE was shown to have no added mortality effect in IPF (Jacob et al., 2017). Patients with IPF have more extensive fibrotic disease, and die rapidly as a consequence of their lung fibrosis. In patients with RA-ILD however, a more limited extent of ILD, and a longer disease course may result in emphysema and the impact of smoking related co-morbidities having a greater influence on patient outcome. The lack of a linkage between ILD extent on CT and CT hombocering presence/definite CT UIP pattern (Raghu et al., 2011) may be explained by RA-ILD patients with extensive disease that have a non-specific interstitial pneumonia rather than a UIP pattern of fibrosis.

There were limitations to the current study. We examined two distinct populations of patients with RA-ILD and identified fundamental demographic differences between the populations, such as the low rate of smoking within the Korean female population when compared to British women with RA-ILD. Yet, we would argue that the use of disparate RA-ILD populations are a fundamental strength of our study and confer a robustness to our results when cardinal observations such as the occurrence of emphysema in never-smokers are replicated across both study cohorts. The relatively small sample size of 116 never-smoker RA-ILD patients in our study resulted in the relatively wide 95% confidence intervals for the presence of emphysema in never-smokers. Whilst our study remains one of the largest detailed

Table 5
Multivariate logistic regression models associated with a) the presence of honeycombing on CT b) an IPF-like definite UIP pattern on CT, in never-smokers and smokers. IPF = idiopathic pulmonary fibrosis, ILD = interstitial lung disease extent. Unadjusted odds ratios are shown in brackets.

| Smoking status   | Dependent variable               | Odds ratio ((unadj)/adj) | 95.0% confidence interval | P value |
|------------------|---------------------------------|--------------------------|---------------------------|---------|
| Never smoker     | Honeycombing presence (yes)     | (1.04) 1.96              | 1.02                      | 1.10    | 0.005 |
|                  | Age (years)                     | (2.30) 0.90              | 0.19                      | 4.21    | 0.89  |
|                  | Gender (Male = 1)               | (1.01) 1.01              | 0.99                      | 1.03    | 0.42  |
|                  | ILD extent (%)                  | (3.53) 5.05              | 1.64                      | 15.56   | 0.005 |
|                  | Emphysema presence (Yes = 1)    | (1.05) 1.04              | 1.02                      | 1.07    | 0.001 |
| Smoker           | Honeycombing presence (yes)     | (1.03) 1.03              | 0.99                      | 1.08    | 0.17  |
|                  | Age (years)                     | (2.59) 2.04              | 0.78                      | 5.30    | 0.15  |
|                  | Gender (Male = 1)               | (1.05) 1.04              | 1.02                      | 1.07    | 0.001 |
|                  | ILD extent (%)                  | (3.46) 3.23              | 1.21                      | 8.62    | 0.02  |
|                  | Emphysema presence (Yes = 1)    | (1.02) 1.01              | 0.99                      | 1.03    | 0.29  |
|                  | Smoking pack year history       | (1.06) 1.09              | 1.04                      | 1.14    | 0.0004|
|                  | Age (years)                     | (0.70) 0.27              | 0.06                      | 1.32    | 0.11  |
|                  | Gender (Male = 1)               | (0.98) 0.97              | 0.94                      | 1.00    | 0.05  |
|                  | ILD extent (%)                  | (1.81) 4.36              | 1.44                      | 13.20   | 0.009 |
|                  | Emphysema presence (Yes = 1)    | (1.01) 0.99              | 0.95                      | 1.04    | 0.79  |
|                  | Smoking pack year history       | (9.66) 7.61              | 1.62                      | 35.79   | 0.01  |
|                  | Age (years)                     | (1.02) 1.01              | 0.98                      | 1.03    | 0.66  |
|                  | Gender (Male = 1)               | (3.92) 4.64              | 1.24                      | 17.36   | 0.02  |
|                  | ILD extent (%)                  | (1.02) 1.02              | 1.00                      | 1.04    | 0.06  |

Please cite this article as: Jacob, J., et al., Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.038
examinations of emphysema extent on CT in RA-ILD patients, larger multicentred studies would be important to validate our observations.

As we examined a respiratory and not a rheumatological database for our study, we were limited with regard to the serological information we were able to analyze. We had no information on patient symptom duration (both respiratory and rheumatological) prior to presentation to either tertiary center, or information on the cause of death in the study population. Furthermore, as tertiary care centers, we do not always receive comprehensive information regarding patient management at local primary or secondary care centers, where treatment regimens such as dose and duration of steroid treatment, and choice of steroid sparing agents can vary widely. As an a priori decision, we intentionally chose not to try to quantify steroid dosages at the time of presentation with RA-ILD as many patients may have had RA pre-existing for some years before the development of symptomatic ILD. During this pre-symptomatic period, patients may have received steroids and steroid sparing agents for some time, with the result that knowledge of steroid use at a single point in time, or for the duration of symptomatic ILD, is likely to have only provided part of the patients treatment profile, and its effect on lung disease.

In conclusion, our study has demonstrated that 27% of RA-ILD patients that have never-smoked have emphysema visible on CT. We have shown that in both never-smokers and smokers, the presence of emphysema independently associates with the presence of honeycombing on CT and the negatively-prognostic CT-UIP pattern. We have also demonstrated that CPFE is associated with a worsened outcome in RA-ILD, following correction for baseline disease severity, when compared patients without emphysema.

Declaration of Interests

Dr. Jacob reports personal fees from Boehringer Ingelheim outside the current work.

Prof Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D, UCB and Novartis and has received consultancy or speakers fees from Apellis, Astra Zeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GlaxoSmithKline R&D, Lanthio, InterMune, ProMetic, Roche, Sanofi-Aventis, Takeda and UCB outside the current work.

Dr. Renzoni reports personal fees from Roche, Boehringer Ingelheim, and Takeda, outside the submitted work.

Dr. Devaraj reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work.

Prof Wells reports personal fees from Intermune, Boehringer Ingelheim, Gilead, MSD, Roche, Bayer, and Chiesi outside the submitted work.

Dr. Song reports personal fees from Boehringer Ingelheim, Sanofi and Gilead outside the current work, and was also supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C1061) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1A2B4016318).

The work was supported by the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.

Authors Contributions

JJ, JWS, HYY, DSK, AD, MK, TM, GC, JB, WLW, FA, ER, AUW were all involved in data collection, analysis and interpretation for the study. JJ and AUW were also involved in the conception and design of the study and writing of the manuscript.

Acknowledgement

There is no funding source to declare for the current study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.01.038.

References

Aleta et al., 2010. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69 (9), 1508–1588.

Antoniou, K.M., Walsh, S.L., Hassell, D.M., et al., 2013. Smoker-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. Respirology 18 (8), 1191–1196.

Antoniou, K.M., Margaritopoulos, G.A., Goh, N.S., et al., 2015. Combined pulmonary fibrosis-lung lymphoma in scleroderma lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheum. 68 (4), 1004–1012.

Assayag, D., Lubin, M., Lee, J.S., King, T.E., Collard, H.R., Ryerson, C.J., 2014. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirol. 19 (8), 1492–1503.

Bieber, V., Cohen, A.D., Freud, T., Agramon-Levin, N., Gertel, S., Amital, H., 2013. Autoimmune smoke and fire—coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis. Rheumatology, 56 (2), 261–266.

Boedt, A., Maury, G., Jamart, J., Dahlpvist, C., 2013. Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis. Respir. Med. 107 (11), 1781–1788.

Cottin, V., Nunes, H., Brillert, P.Y., et al., 2005. Combined pulmonary fibrosis and emphysema: a distinct unrecognised entity. Eur. Respir. J. 26, 586–593.

Cottin, V., Nunes, H., Mouthon, L., et al., 2011. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 63 (1), 295–304.

Doyle, T.J., Lee, J.S., Dellapapa, P.F., et al., 2014. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 145 (3), 454–463.

Feghali-Bostwick, C.A., Gadgil, A.S., Otterbein, L.E., et al., 2008. Autoantibodies in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177 (2), 156–163.

Ghuoco, B.R., Avila, N.A., Chow, C.K., et al., 2008. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arthritis. Immunol. 165 (2), 159–166.

Inomata, M., Ikishima, S., Awano, N., et al., 2014. An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. BMC Pulm Med 14, 104.

Jacob, J., Bartolomai, R., Rajagopalan, S., et al., 2017. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur. Respir. J. 50.

Kelly, C.A., Saravanan, V., Nisar, M., et al., 2014. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology (Oxford) 53, 1676–1682.

Kim, E.J., Elicker, B.M., Maldonado, F., et al., 2010. Usual interstitial pneumonitis in rheumatoid arthritis-associated interstitial lung disease. Eur. Respir. J. 35 (6), 1322–1328.

KakugantiM, D., Hermansson, M., Ulfgreen, A.-K., et al., 2008. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 67 (10), 1488–1492.

McGuire, K., Avina-Zubieta, J.A., Esdaile, J.M., et al., 2017. Risk of Incident Chronic Obstructive Pulmonary Disease (COPD) in Rheumatoid Arthritis: A Population-Based Cohort Study. Arthritis Care Res. Majia, M., Carrillo, G., Rojas-Serrano, J., et al., 2009. Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension. In: CHEST Journal 136 (1), 10–15.

Mura, M., Zompatori, M., Pacilli, A.M., Faso, L., Schiavina, M., Fabbi, M., 2006. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. RespirCare 51 (3), 257–265.

Packard, T.A., Li, Q.Z., Cosgrove, G.P., Bowler, R.P., Cambier, J.C., 2013. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol. Res. 55 (1), 48–57.

Raghu, G., Collard, H.R., Egan, J.J., et al., 2011. An official ATS/ERS/JSALAT statement: idiopathic pulmonary fibrosis—evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788–824.

Rangel-Moreno, J., Hartson, L., Navarro, C., Gaxiola, M., Selman, M., Randall, T.D., 2006. In-dwelling bronchos–-associated lymphoid tissue (IBALT) in patients with pulmonary complications of rheumatoid arthritis. J. Clin. Invest. 116 (12), 3183–3194.

Rocha-Munoz, A.D., Ponce-Guarneres, M., Gomez-Nava, J.L., et al., 2015. Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis. J. Immunol Res 2015, 151626.

Ryerson, C., Hartman, T., Elicker, B., et al., 2013. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 144, 234–240.

Saag, K.G.K., Koehne, R.K., Georgou, T.A., Rachow, J.W., Hunninghake, G.W., Schwartz, D. A., 1996. Rheumatoid arthritis lung disease. Determinants of radiographic and physiological abnormalities. Arthritis Rheum. 39, 1719–1719.

Schally, S.W., Petersen, J., Law, S.C., et al., 2013. A molecular basis for the association of the -em-HLA-DRB1-em- locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210 (12), 2369–2382.

Shen, T.C., Lin, C.L., Chen, C.H., et al., 2014. Increased risk of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a population-based cohort study. QJM 107 (7), 537–543.

Please cite this article as: Jacob, J., et al., Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.038.
Tsuchiya, Y., Takayanagi, N., Sugiura, H., et al., 2011. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur. Respir. J. 37 (6), 1411–1417.

Volonte, D., Kahkonen, B., Shapiro, S., Di, Y., Galbiati, F., 2009. Caveolin-1 expression is required for the development of pulmonary emphysema through activation of the ATM-p53-p21 pathway. J. Biol. Chem. 284 (9), 5462–5466.

Vuorinen, K., Ohlmeier, S., Leppärinta, O., Sämenkivi, K., Myllärniemi, M., Kinnula, V.L., 2008. Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis. J. Histochem. Cytochem. 56 (10), 951–959.

Yunt, Z.X., Chung, J.H., Hobbs, S., et al., 2017. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respir. Med. 126, 100–104.

Zandvoort, A., Postma, D.S., Jonker, M.R., Noordhoek, J.A., Vos, J.T.W.M., Timens, W., 2008. Smad gene expression in pulmonary fibroblasts: indications for defective ECM repair in COPD. Respir. Res. 9 (1), 83.

Zhang, C., Yao, M.-Y., Lu, P., et al., 2014. Hypomethylation of perforin regulatory elements in CD4+ T cells from rat spleens contributes to the development of autoimmune emphysema. Respirology 19 (3), 376–381.